6BAA image
Entry Detail
PDB ID:
6BAA
EMDB ID:
Keywords:
Title:
Cryo-EM structure of the pancreatic beta-cell KATP channel bound to ATP and glibenclamide
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2017-10-12
Release Date:
2017-11-01
Method Details:
Experimental Method:
Resolution:
3.63 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:ATP-sensitive inward rectifier potassium channel 11
Chain IDs:A, B, C, D
Chain Length:390
Number of Molecules:4
Biological Source:Rattus norvegicus
Polymer Type:polypeptide(L)
Description:ATP-binding cassette sub-family C member 8
Chain IDs:E, F, G, H
Chain Length:1582
Number of Molecules:4
Biological Source:Cricetus cricetus
Primary Citation
Anti-diabetic drug binding site in a mammalian KATPchannel revealed by Cryo-EM.
Elife 6 ? ? (2017)
PMID: 29035201 DOI: 10.7554/eLife.31054

Abstact

Sulfonylureas are anti-diabetic medications that act by inhibiting pancreatic KATP channels composed of SUR1 and Kir6.2. The mechanism by which these drugs interact with and inhibit the channel has been extensively investigated, yet it remains unclear where the drug binding pocket resides. Here, we present a cryo-EM structure of a hamster SUR1/rat Kir6.2 channel bound to a high-affinity sulfonylurea drug glibenclamide and ATP at 3.63 Å resolution, which reveals unprecedented details of the ATP and glibenclamide binding sites. Importantly, the structure shows for the first time that glibenclamide is lodged in the transmembrane bundle of the SUR1-ABC core connected to the first nucleotide binding domain near the inner leaflet of the lipid bilayer. Mutation of residues predicted to interact with glibenclamide in our model led to reduced sensitivity to glibenclamide. Our structure provides novel mechanistic insights of how sulfonylureas and ATP interact with the KATP channel complex to inhibit channel activity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures